PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)

• Main Authors: Saeideh Sobati (Author), Amir Shakouri (Author), Mahdi Edalati (Author), Daryoush Mohammadnejad (Author), Reza Parvan (Author), Javad Masoumi (Author), Jalal Abdolalizadeh (Author)
• Format: Book
• Published: Tabriz University of Medical Sciences, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage. PCSK9 adheres to the epidermal growth factor-like repeat A...